Mount Sinai Deploys Flosonics’ Wearable Ultrasound to Optimize ICU Care

What You Should Know:

–   Flosonics Medical, the leader in wearable ultrasound for critical care, today announced that The Mount Sinai Hospital has adopted FloPatch, the first wireless Doppler ultrasound device, in its surgical and transplant intensive care units.

–  This milestone marks the company’s first East Coast deployment, expanding its U.S. footprint and reinforcing growing demand for real-time, individualized fluid management in ICUs.

FloPatch: Enabling Precision Fluid Management in Critical Care Through Real-Time, Non-Invasive Ultrasound

Flosonics Medical, a Canadian medical device company founded in 2015, is advancing critical care through the development of innovative ultrasound technologies. With a mission to enhance patient care and clinical practice, the company combines technology-enabled solutions with cutting-edge clinical research to address longstanding challenges in hemodynamic assessment.

Its flagship product, FloPatch, is a non-invasive, FDA-cleared wearable ultrasound device designed for use in intensive care units. This wireless tool enables clinicians to perform rapid and repeatable hemodynamic assessments in under three minutes—providing real-time blood flow data at the bedside to guide intravenous (IV) fluid management. Unlike traditional methods, which are often invasive or time-intensive, FloPatch offers a streamlined approach that supports immediate and personalized decision-making.

Mount Sinai Hospital in New York became the first institution to deploy FloPatch in its surgical and transplant ICUs following its introduction in April 2025. According to early internal data:

·       42% of patients assessed using FloPatch were found to be unresponsive to fluids.

·       This insight allowed clinicians to avoid unnecessary fluid administration—an intervention associated with potential complications and prolonged hospital stays in non-responsive patients.

By identifying fluid responsiveness quickly, FloPatch supports physiologically guided treatment decisions in high-acuity environments. “The device addresses a longstanding need in critical care for accessible and repeatable bedside assessments,” said Dr. John Oropello, Professor of Surgery and Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Transplant ICU. “It allows our team to make timely, personalized decisions in complex clinical situations.”

Mount Sinai’s adoption of FloPatch underscores a broader shift toward precision medicine in critical care. By moving away from protocolized fluid therapy and toward individualized treatment, the hospital is setting a new benchmark for ICU management. Flosonics Medical continues to support this evolution in care by equipping clinicians nationwide with tools that deliver smarter, safer, and more responsive interventions.